Related Experiment Videos

Patients with difficult-to-treat depression do not exhibit an increased frequency of CYP2D6 allele duplication

A Háber1, O Rideg, P Osváth

  • 1Department of Pharmaceutics, Faculty of Medicine, University of Pécs, Pécs, Hungary.

Pharmacopsychiatry
|June 6, 2013
PubMed

Insights

CYP2D6 genetic variations and predicted metabolic phenotypes were analyzed in patients with difficult-to-treat depression. Findings suggest these genetic factors do not significantly differ from the healthy Hungarian population, but high frequencies of non-functional alleles warrant attention.

Area of Science:

  • Pharmacogenomics
  • Clinical Pharmacy
  • Genetics

Background:

  • Antidepressant treatment failure can stem from altered drug metabolism.
  • Cytochrome P450 family 2 subfamily D member 6 (CYP2D6) plays a crucial role in metabolizing many antidepressants.
  • CYP2D6 genotyping may identify genetic factors contributing to treatment resistance.

Purpose of the Study:

  • To determine CYP2D6 allelic variant frequencies and predicted phenotypes in difficult-to-treat depression patients.
  • To compare these genetic profiles with the healthy Hungarian population.
  • To assess the role of CYP2D6 genetics in antidepressant pharmacotherapy failure.

Main Methods:

  • Genotyping of 55 patients with treatment-resistant depression (failed ≥2 antidepressant trials).
  • Analysis of CYP2D6 allele frequencies and prediction of metabolic phenotypes (UM, EM, IM, PM).
  • Comparison of patient data with existing data from the healthy Hungarian population.

Main Results:

  • No significant differences in CYP2D6 allele frequencies or phenotype distributions between patients and the healthy population.
  • Prevalence of CYP2D6 ultra-rapid metabolizers (UMs), extensive metabolizers (EMs), intermediate metabolizers (IMs), and poor metabolizers (PMs) were similar.
  • High cumulative frequency of non-functional alleles (33.5%) and PM phenotype (14.5%) observed in the patient group.

Conclusions:

  • CYP2D6 genetic variations do not appear to be a primary driver for antidepressant treatment failure in this Hungarian cohort.
  • The study highlights a potentially high prevalence of individuals with poor CYP2D6 metabolism, suggesting possible roles in side effects or non-adherence.
  • Further investigation into unrecognized side effects and adherence issues is warranted in patients with difficult-to-treat depression.

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...